Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg
Treatment approaches near the end of life have markedly changed in skin cancer centers in Germany over recent years, with ICI prescribed less frequently in the end-of-life phase. In contrast, TT are frequently administered, even within the last 30 days of life. It should also be considered that discontinuation of TT can result in rapid tumor progression. Due to the oral administration and a low rate of severe toxicity, TT appear to be a suitable treatment option, even in the end-of-life situation of melanoma patients.
Authors
- Carsten Weishaupt (ORCID: https://orcid.org/0000-0003-1195-2106)
- Patrick Terheyden (ORCID: https://orcid.org/0000-0002-5894-1677)
- Carola Berking
- Jochen Sven Utikal (ORCID: https://orcid.org/0000-0001-5316-0241)
- Rudolf Alexander Herbst (ORCID: https://orcid.org/0000-0002-4238-9486)
- Ralf Gutzmer (ORCID: https://orcid.org/0000-0001-7921-2820)
- Anja Gesierich
- Daniela Göppner
- Michael Weichenthal (ORCID: https://orcid.org/0000-0002-9060-4961)
- Claudia Pföhler (ORCID: https://orcid.org/0000-0003-0384-114X)
- Sebastian Haferkamp (ORCID: https://orcid.org/0000-0002-3894-8345)
- Andrea Forschner (ORCID: https://orcid.org/0000-0002-6185-4945)
- R.U. Wahl (ORCID: https://orcid.org/0000-0003-1748-3689)
- Katharina C. Kähler (ORCID: https://orcid.org/0000-0001-9953-0893)
- Dirk Schadendorf (ORCID: https://orcid.org/0000-0003-3524-7858)
- Friedegund Meier (ORCID: https://orcid.org/0000-0003-4340-9706)
- Martin Gschnell
- Selma Ugurel (ORCID: https://orcid.org/0000-0002-9384-6704)
- Frank Meiß (ORCID: https://orcid.org/0000-0002-4044-9094)
- Markus Reitmajer (ORCID: https://orcid.org/0000-0002-7134-1043)
- Marlene Garzarolli
- Carmen Loquai
- Ulrike Leiter (ORCID: https://orcid.org/0000-0002-8019-1577)
- Peter Mohr
- Ewan Andrew Langan (ORCID: https://orcid.org/0000-0001-7624-2784)
- Martin Kaatz (ORCID: https://orcid.org/0000-0002-0650-2576)
- Michael Sachse
- Lena Nanz
- Max Schlaak
- Jens Ulrich
- Ivonne Kellner
- Imke von Wasielewski
- Kai‐Martin Thoms
Institutions
- University of Freiburg (DE)
- Philipps University of Marburg (DE)
- German Cancer Research Center (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Heidelberg University (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- University Medical Center Freiburg (DE)
- University Hospital Heidelberg (DE)
- University of Manchester (GB)
- University Hospital Regensburg (DE)
- Medizinische Hochschule Hannover (DE)
- Humboldt-Universität zu Berlin (DE)
- Düsseldorf University Hospital (DE)
- SRH Wald-Klinikum Gera (DE)
- University Hospital Münster (DE)
- University Hospital Schleswig-Holstein (DE)
- Universitätsmedizin Göttingen (DE)
- Essen University Hospital (DE)
- Universitätsklinikum Würzburg (DE)
- Elbe Kliniken Stade-Buxtehude (DE)
- Helios Klinikum Erfurt (DE)
- University Medical Centre Mannheim (DE)
- University Hospital Carl Gustav Carus (DE)
- Johannes Wesling Klinikum Minden (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Duisburg-Essen (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- University of Tübingen (DE)
- RWTH Aachen University (DE)
- Ruhr University Bochum (DE)
- Saarland University (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1509886
- Citations
- 2
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.61